🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma

RecruitingNAAges 18 Years - 80 YearsAllRuijin Hospital
NCT06596954 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignant tumors. Although neoadjuvant chemoradiotherapy combined with surgery has significantly improved the survival rate of patients with locally advanced esophageal cancer, approximately half of the patients will experience local regional recurrence or distant metastasis. Lymphocytes are crucial immune cells in the human body, playing a key role in combating infections and tumor development. In recent years, an increasing body of research has indicated that lymphocyte depletion is a significant factor associated with poor prognosis in various solid tumors, including esophageal cancer. The lymphocyte depletion caused by radiotherapy has garnered considerable attention from oncologists. However, there is still a lack of prospective clinical research data on lymphocyte protection in thoracic tumors. Therefore, this

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients are able to understand and are willing to participate in the trial, and a signed consent form can be obtained; 2. Pathologically confirmed esophageal squamous cell carcinoma; 3. locally advanced ESCC (cT3-4 or N+); 4. the age of patients should be more than 18 years, and less than 80 years; 5. aged between 18 and 80 years; 6. KPS score of patients should be more than 80 Exclusion Criteria: 1. diagnosis of metastatic esophageal cancer; 2. Patient refuses to receive systemic drug treatment; 3. clinical diagnosis of pleural metastasis or malignant pleural effusion; 4. Pregnant or breastfeeding women; 5. Severe non-cancerous medical comorbidities that affect the implementation of radiotherapy.
💊

What it tests

  • lymphocyte-sparing radiotherapy
  • conventional radiotherapy
📍

Where

1 site
Ruijin hospital, Shanghai jiaotong university school of medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy